Analyst consensus rating
Alterity Therapeutics Analyst Rating: none
Direct answer
Alterity Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.25.
Forecast evidence checked November 13, 2026.
Get free Alterity Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.10
- Average price target
- $13.25
- High price target
- $16.00
- Low price target
- $10.00
- Low target gap
- +377.3%
- Target upside
- +532.5%
- High target gap
- +663.7%
- Target range width
- 286.4%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Alterity Therapeutics?
Alterity Therapeutics has a verified none consensus. The same dataset has an average price target of $13.25.
How far are Alterity Therapeutics's low and high targets from the recorded price?
The low target implies +377.3%, while the high target implies +663.7%.
How many analysts are included in Alterity Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Alterity Therapeutics's target upside or downside calculated?
The average target of $13.25 is divided by the recorded price of $2.10, then one is subtracted to produce +532.5%. This does not guarantee a future return.
When was Alterity Therapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.